Loan & DebtJun 16, 2026, 04:17 PM
CTT Pharma May Raise Up To $10M Via Equity Line of Credit
AI Summary
CTT Pharmaceutical Holdings, Inc. has filed an S-1 form detailing an Equity Line of Credit (ELOC) agreement with RH2, allowing the company to potentially sell up to 6,250,000 shares of common stock for up to $10 million. While the company will not receive proceeds from the initial sale by the Selling Stockholder, it may receive funds from subsequent sales under the ELOC, intended for working capital and operational improvements. The company expresses concern about potential dilution at current stock prices and plans to limit ELOC usage until the stock price increases.
Key Highlights
- CTT Pharmaceutical Holdings, Inc. may receive up to $10 million from the sale of common stock to a Selling Stockholder under an Equity Line of Credit (ELOC).
- The ELOC agreement was established on September 19, 2025, with RH2 acting as the Selling Stockholder.
- The company will not receive proceeds from the initial sale of shares by the Selling Stockholder but may receive proceeds from future sales under the ELOC.
- Proceeds from the ELOC are intended for working capital, strategic initiatives, and general corporate purposes, with a priority for equipment to bring manufacturing in-house.
- The company aims to limit the use of the ELOC to minimize dilution, especially at current low stock prices, and plans to raise limited funds below $0.20 per share.
- At current stock prices, approximately 166 million shares would need to be issued to raise $10 million, representing significant dilution.
Price Impact
More from CTTH